Curadev

Executive Summary

Curadev is a London-based, clinical-stage biotech company dedicated to discovering novel small molecule therapeutics for intractable diseases, with a focus on immuno-oncology, neuroinflammation, and metabolic disorders. Founded in 2015, the company employs a target-centric approach that combines innovative screening with classical medicinal chemistry to modulate next-generation drug targets. By addressing areas with high unmet medical need, Curadev aims to develop first-in-class or best-in-class therapies that can significantly improve patient outcomes. Curadev has advanced its lead program into Phase 1 clinical trials, marking a key milestone in its transition from preclinical to clinical development. While specific pipeline details are not publicly disclosed, the company's expertise in immuno-oncology and neuroinflammation positions it well for potential breakthroughs. Upcoming catalysts include the completion of ongoing Phase 1 studies, which could provide initial proof-of-concept data, and possible preclinical data presentations at major scientific conferences. Additionally, the company may seek strategic partnerships or licensing deals to accelerate development and expand its pipeline. With a focused strategy and a strong scientific foundation, Curadev represents a promising opportunity in the small-molecule therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 1 trial for lead candidate70% success
• H1 2027Presentation of preclinical data at a major oncology conference80% success
• H2 2026Announcement of a strategic partnership or licensing deal50% success